Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.
Coronary diseaseDay 3

SOLACI-SOCIME 2022 | Rotablation in Superficial Femoral Angioplasty, by Dr. Alejandro Goldsmit

solaci
solaci
572
0

Read the most outstanding articles from the third day of the SOLACI-SOCIME 2022 Congress.

In this case, consult the presentation by Dr. Alejandro Goldsmit, entitled “Rotablation in Superficial Femoral Angioplasty”.

12.00-12.15-ALEJANDRO-Goldsmit-Rota-ses-57

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
SOLACI-SOCIME 2022 | Reemplazo transcatéter de válvula pulmonar Experiencia con Melody y Harmony, by Dr. Alejandro Torres
Next article
SOLACI-SOCIME 2022 | Neo commisural alignment and coronary overlap after TAVI, by Dr. Luis Nombela Franco
solaci
solaci

More articles by this author

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

Dr. Juan Manuel Pérez - 0
The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Dr. Juan Manuel Pérez - 0
Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...

EuroPCR 2026 | Is localized anticoagulation the next step for coronary stents?

Dr. Juan Manuel Pérez - 0
The DESyne BDS Plus stent was developed as a thin-strut, bioabsorbable polymer drug-eluting stent that combines sirolimus release with two anticoagulant agents (rivaroxaban and...

EuroPCR 2026 | Restoring vascular physiology: 4-year results of the BIOADAPTOR-RCT

Dr. Juan Manuel Pérez - 0
Despite advances in drug-eluting stents, device-related events continue to increase beyond the first year after angioplasty. In this context, the DynamX system emerged as...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Coronary disease

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However,...
Dr. Juan Manuel Pérez -
SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

Dr. Andrés Rodríguez - 0
This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

Dr. Juan Manuel Pérez - 0
The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Dr. Juan Manuel Pérez - 0
Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...